[Study on clinicopathologic features and immunophenotype of 114 cases of renal cell carcinoma].
OBJECTIVE
To study the clinicopathologic features and immunophenotype of renal cell carcinomas, and to discuss their diagnostic value.


METHODS
The clinicopathologic features of 114 cases of renal cell carcinoma were reviewed and categorized on the basis of 2004 WHO classification. Immunohistochemical study for a panel of antibodies (including CK, CD10, vimentin, CD117, AMACR, CK7 and TFE3) was carried out. The follow-up data, if available, were also analyzed.


RESULTS
The cases were reclassified into 5 subtypes, including 77 cases (67.5%) of clear cell carcinoma (CCRCC), 11 cases (9.6%) of papillary renal cell carcinoma (PRCC), 14 cases (12.3%) of chromophobe renal cell carcinoma (chrRCC), 10 cases (8.8%) of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions (Xp11.2RCC) and 2 cases (1.8%) of unclassified renal cell carcinoma (unRCC). Immunohistochemical study showed that the expression rates of CK, CD10 and vimentin in CCRCC were 93.5% (72/77), 93.5% (72/77) and 75.3% (58/77), respectively. On the other hand, all the 11 cases of PRCC studied were positive for AMACR. The expression rate of CD117 in chrRCC was 78.5% (11/14). In the 10 cases of Xp11.2 RCC studied, the expression rates of TFE3, AMACR, CD10 and CK were 100% (10/10), 100% (10/10), 90% (9/10) and 70% (7/10), respectively.


CONCLUSIONS
The various subtypes of renal cell carcinomas are heterogeneous in histologic appearance and demonstrate distinctive immunophenotype. The expressions of CD10, vimentin, CD117, AMACR, CK7 and TFE3 are helpful in the differential diagnosis.
Zou
Hong
H
Department of Pathology, Medical College, Shihezi University, Xinjiang 832002, China.
Pang
Li-juan
LJ
Hu
Wen-hao
WH
Li
Feng
F
Li
Hong-an
HA
Jiang
Jin-fang
JF
Liang
Wei-hua
WH
Sun
Zhen-zhu
ZZ
Wang
Chun
C
Lang
Jian-yong
JY
D018262:Adenocarcinoma, Clear Cell / Q000473:pathology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D002291:Carcinoma, Papillary / Q000276:immunology / Q000473:pathology; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D005260:Female; D050939:Gene Fusion; D006801:Humans; D016130:Immunophenotyping; D007680:Kidney Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000032:analysis; D019998:Racemases and Epimerases / Q000032:analysis / Q000235:genetics*; D014178:Translocation, Genetic; D014746:Vimentin / Q000032:analysis; D014944:World Health Organization; D055815:Young Adult
D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; D014408:Biomarkers, Tumor; C069203:TFE3 protein, human; D014746:Vimentin; D015260:Neprilysin; D019998:Racemases and Epimerases; C108352:alpha-methylacyl-CoA racemase